Impact on survival of different treatments for myelodysplastic syndromes (MDS).
暂无分享,去创建一个
U. Germing | G. Kobbe | R. Haas | A. Giagounidis | N. Gattermann | C. Strupp | A. Kündgen | K. Nachtkamp
[1] J. Byrd,et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. , 2007 .
[2] U. Germing,et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes , 2007, Cancer.
[3] G. Mufti,et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.
[4] G. Mufti,et al. C025 Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin , 2007 .
[5] R. Fanin,et al. P144 Thalidomide alone or in combination with other agents for the treatment of myelodysplastic syndromes (MDS) , 2007 .
[6] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[7] P. Musto,et al. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. , 2006, Leukemia research.
[8] C. Steidl,et al. P-112 Results of a phase II trial with valproic acid (VPA) alone or in combination with all-trans-retinoic acid (ATRA) in 71 patients with myelodysplastic syndromes or SAML/MDS , 2005 .
[9] J. Issa,et al. P-119 Advanced myelodysplastic syndromes (MDS): Patient subset results of a phase III trial comparing decitabine (DAC) vs. supportive care (SC) , 2005 .
[10] U. Germing,et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.
[11] H. Heimpel,et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.
[12] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] U. Germing,et al. Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.
[14] P. Venugopal,et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.
[15] U. Germing,et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. , 2000, Leukemia research.
[16] J. Bennett,et al. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. , 2000, International journal of hematology.
[17] F. Appelbaum,et al. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. , 1998, Leukemia.
[18] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.
[19] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[20] U. Germing,et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.